Santhanam Haripriya, Ong Jacqueline Sm, Shen Liang, Tan Poh Lin, Koh Pei Lin
Department of Paediatrics, National University Health System, Singapore.
Ann Acad Med Singap. 2017 Feb;46(2):44-49.
This study aimed to investigate the risk factors associated with mortality in haematopoietic stem cell transplant (HSCT) patients admitted to our paediatric intensive care unit (PICU) over an 8-year period.
A retrospective chart review was conducted of all HSCT patients requiring PICU admission at our centre (a tertiary care university hospital in Singapore) from January 2002 to December 2010. Chief outcome measures were survival at the time of PICU discharge and survival at 6 months after initial PICU admission.
Ninety-eight patients underwent HSCT during this period; 18 patients (18%) required 24 PICU admissions post-HSCT. The overall survival to PICU discharge was 62.5%. Of those who survived discharge from the PICU, 33% died within 6 months of discharge. Non-survivors to PICU discharge had a higher incidence of sepsis (89% vs 33%, = 0.013) and organ failure as compared to survivors (cardiovascular failure 100% vs 20%, = 0.0003; respiratory failure 89% vs 20%, = 0.002; and renal failure 44% vs 7%, = 0.047). Mortality rates were higher in patients requiring mechanical ventilation (70% vs 14%, = 0.010) and inotropic support (70% vs 14%, = 0.010). Mortality in all patients with renal failure requiring haemodialysis (n = 4) was 100%. Presence of 3 or more organ failures was associated with 80% mortality ( = 0.003).
Sepsis, multiple organ failure and the need for mechanical ventilation, inotropes and especially haemodialysis were associated with increased risk of mortality in our cohort of HSCT patients.
本研究旨在调查在8年期间入住我院儿科重症监护病房(PICU)的造血干细胞移植(HSCT)患者的死亡相关危险因素。
对2002年1月至2010年12月期间在我院中心(新加坡一家三级护理大学医院)因HSCT而需入住PICU的所有患者进行回顾性病历审查。主要结局指标为PICU出院时的生存率以及初次入住PICU后6个月的生存率。
在此期间,98例患者接受了HSCT;18例患者(18%)在HSCT后需要24次入住PICU。PICU出院时的总体生存率为62.5%。在那些从PICU存活出院的患者中,33%在出院后6个月内死亡。与幸存者相比,PICU出院时的非幸存者败血症发生率更高(89%对33%,P = 0.013),器官衰竭发生率也更高(心血管衰竭100%对20%,P = 0.0003;呼吸衰竭89%对20%,P = 0.002;肾衰竭44%对7%,P = 0.047)。需要机械通气的患者死亡率更高(70%对14%,P = 0.010)以及需要使用血管活性药物支持的患者死亡率更高(70%对14%,P = 0.010)。所有需要血液透析的肾衰竭患者(n = 4)死亡率为100%。出现3种或更多器官衰竭与80%的死亡率相关(P = 0.003)。
败血症、多器官衰竭以及需要机械通气、血管活性药物支持,尤其是血液透析与我们这组HSCT患者的死亡风险增加相关。